Substance / Medication

Hydroxyprogesterone caproate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Racial and ethnic representation in 17-hydroxyprogesterone caproate preterm birth prevention studies: a systematic review.
Smith Megan M, Weber Jeremy M, Truong Tracy et al. · J Perinat Med · 2022
PMID: 36027908Meta-Analysis
Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
Lichter Katie E, Sheffield Jeanne, Graham Ernest M et al. · J Matern Fetal Neonatal Med · 2020
PMID: 30626240Meta-AnalysisFull text (PMC)
17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke Ahizechukwu C, Sheffield Jeanne, Graham Ernest M · Obstet Gynecol · 2019
PMID: 30741815Meta-AnalysisFull text (PMC)
A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Fernandez-Macias Rosa, Martinez-Portilla Raigam J, Cerrillos Lucas et al. · Int J Gynaecol Obstet · 2019
PMID: 31402445Meta-Analysis
Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Eke Ahizechukwu C, Sheffield Jeanne, Graham Ernest M · Acta Obstet Gynecol Scand · 2019
PMID: 30339274Meta-AnalysisFull text (PMC)
17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.
Combs C A, Schuit E, Caritis S N et al. · BJOG · 2016
PMID: 26663620Meta-AnalysisFull text (PMC)
17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
Saccone Gabriele, Suhag Anju, Berghella Vincenzo · Am J Obstet Gynecol · 2015
PMID: 25659469Meta-Analysis
Effect of 17-Hydroxyprogesterone Caproate on Interleukin-6 and Tumor necrosis factor-alpha in expectantly managed early-onset preeclampsia.
Othman Mahmoud A, Badawy Eman R, Sobh Ahmed M A et al. · Egypt J Immunol · 2023
PMID: 37031413RCT
Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis Steve N, Costantine Maged M, Clark Shannon et al. · Am J Obstet Gynecol MFM · 2023
PMID: 37100349RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Hydroxyprogesterone caproate (substance)
SNOMED CT
126111009
UMLS CUI
C0044971

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.